Skip to main content

Table 2 Part 2. Baseline clinical data of controlled study (n = 50)

From: Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial

Variables Tranexamic acid (n = 24) Placebo (n = 26) P value
Demographic    
   Age, years 66 (63–70) 67 (62–71) 0.91
   Male gender, number (percentage) 12 (50) 15 (57) 0.58
   Body mass index, kg/m2 28 (25.8–30.1) 28.1 (36.4–29.7) 0.98
   Parsonnet score 13.1 (11.8–15.5) 17.5 (13.7–21.3) 0.07
Comorbidity    
Cardiopathy, number (percentage)    
   Coronary 13 (54) 12 (46) 0.71
   Valve 9 (38) 10 (39) 0.68
   Mixed 2 (8) 4 (15) 0.44
Medical treatment    
   Angiotensin-converting enzyme inhibitors, number (percentage) 11 (61) 7 (39) 0.16
   Calcium channel blockers, number (percentage) 6 (60) 4 (40) 0.39
Preoperative parameters    
   Platelet count, × 103/mL 210 (186–234) 210 (186–239) 0.68
   Hemoglobin, g/dL 14.1 (13.5–14.6) 13.6 (12.8–14.4) 0.42
   International normalized ratio 1.08 (1.05–1.12) 1.09 (1.05–1.14) 0.97
   D-dimer, ng/mL 250 (166–333) 275 (215–325) 0.34
   Plasminogen activator inhibitor 1, ng/mL 34.2 (29–39.5) 35.2 (29.4–41.1) 0.95
Surgical data    
   Cardiopulmonary bypass time, minutes 82 (71–94) 85 (74–96) 0.30
   Aortic clamping time, minutes 51 (44–58) 55 (47–62) 0.35
   Temperature after cardiopulmonary bypass, degrees Celsius 35.3 (34.9–35.6) 35.1 (34.7–35.3) 0.24
   Total heparin dose, UI/kg 430 (400–470) 420 (400–440) 0.69
   Total protamine dose, mg/kg 2.7 (2.5–3) 2.7 (2.6–2.9) 0.72
   Blood salvage device, mL 681 (605–756) 764 (694–833) 0.12
  1. Values are expressed as mean and 95% confidence interval or as frequency and percentage.